Skip to content

Coffee for Optimal Metabolite Profile

Coffee for Optimal Metabolite Profile

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05757154
Enrollment
12
Registered
2023-03-07
Start date
2023-03-31
Completion date
2023-07-03
Last updated
2023-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The aim of this project is to evaluate metabolite profile after consumption of three types of coffee differing in type of bean, degree of roasting and preparation method. Metabolite profiles will be evaluated after a) a single dose b) 3-day consumption. The study will be carried out as a three-way cross-over design with three different types of coffee. Wash-out periods where participants consume their habitual diet are implemented between all intervention periods. The first day of intervention (single dose) includes postprandial measurements during 13 hours.

Interventions

OTHERDiet

All intervention arms are coffee. Three different types of coffee is tested. Differences in type of bean, degree of roasting and preparation method.

Sponsors

Paulig Group
CollaboratorUNKNOWN
Chalmers University of Technology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Females and males * 18 to 80 years of age * Body mass index (BMI) 18.5-30.0 kg/m2 * Fasting glucose ≤ 6.1 mmol/l * Low density lipoprotein (LDL) cholesterol ≤ 5.30 mmol/l * Triglycerides ≤ 2.60 mmol/l * Signed informed consent

Exclusion criteria

* Food allergies or intolerances preventing consumption of any products included in the study. * Unable to sufficiently understand written and spoken Swedish to provide written consent and understand information and instructions from the study personnel. * Pregnant, lactating or planning a pregnancy during the study period. * Antibiotic use for the last 3 months. * Blood donation or participation in a clinical study with blood sampling within 30 days prior to screening visit and throughout the study. * History of stomach or gastrointestinal conditions (Inflammatory bowel disease, Chron's disease, malabsorption, colostomy, bowel resection, gastric bypass surgery etc.) * Previous major gastrointestinal surgery * Have type I diabetes * Thyroid disorder

Design outcomes

Primary

MeasureTime frameDescription
Plasma concentrations of key metabolites derived from chlorogenic acid, caffeine, trigonelline and diterpenes.24 hoursDifference in the plasma concentrations between the different types of coffee comparing before (baseline) and after single dose intervention.
Plasma concentration-time profile over 24 hours (AUC) of key metabolites derived from chlorogenic acid, caffeine, trigonelline and diterpenes.24 hoursDifference in plasma AUC between the different types of coffee for each biomarker candidate.
Urine concentrations of key metabolites derived from chlorogenic acid, caffeine, trigonelline and diterpenes.24 hoursDifference in the urine concentrations between the different types of coffee comparing before (baseline) and after single dose intervention.
Plasma kinetic profiles of key metabolites derived from chlorogenic acid, caffeine, trigonelline and diterpenes.24 hoursCmax will be estimated.

Secondary

MeasureTime frameDescription
Gut microbiome4 daysFecal samples will analyzed for composition of the gut microbiome, baseline compared with after 4 days of intervention products.
Plasma concentrations of key metabolites derived from chlorogenic acid, caffeine, trigonelline and diterpenes.4 daysDifference in the plasma concentrations between the different types of coffee comparing before (baseline) and after single dose and three days intervention.
Blood concentrations of key metabolites derived from chlorogenic acid, caffeine, trigonelline and diterpenes.13 hoursEvaluate new simple sampling techniques using dried blood spots.
Urine concentrations of key metabolites derived from chlorogenic acid, caffeine, trigonelline and diterpenes.4 daysDifference in the urine concentrations between the different types of coffee comparing before (baseline) and after single dose and three days intervention.
Plasma metabolites4 daysUntargeted metabolomics will be performed using established methods for plasma. Analyzed exploratorily using untargeted metabolomics to find potential biomarker panels that reflect coffee consumption. Baseline compared with after intervention products.
Urine metabolites24 hoursUntargeted metabolomics will be performed using established methods for urine. Analyzed exploratorily using untargeted metabolomics to find potential biomarker panels that reflect coffee consumption. Baseline compared with after intervention products.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026